Is Abbott Laboratories a Sell?

Should you sell Abbott Laboratories (NYSE: ABT  ) today?

The decision to sell a stock you've researched and followed for months or years is never easy. But if you fall in love with your stock holdings, you risk becoming vulnerable to confirmation bias -- listening only to information that supports your theories, and rejecting any contradictions.

In 2004, longtime Fool Bill Mann called confirmation bias one of the most dangerous components of investing. This warning has helped my own investing throughout the Great Recession. Now I want to help you identify potential sell signs on popular stocks within our 4-million-strong Fool.com community.

Today I'm laser-focused on Abbott Laboratories, ready to evaluate its price, valuation, margins, and liquidity. Let's get started!

Don't sell on price
Over the past 12 months, Abbott has risen by 2.4% versus an S&P 500 return of 11.3%. Investors are no doubt disappointed with their returns, but is now the time to cut and run? Not necessarily. Short-term underperformance alone is not a sell sign. The market may be missing the critical element of your investing thesis. For historical context, let's compare Abbott's recent price with its 52-week and five-year highs. I've also included a few other businesses in the same industry or a related one.

Company

Recent Price

52-Week High

5-Year High

Abbott Laboratories $53.17 $56.79 $61.10
Johnson & Johnson (NYSE: JNJ  ) $63.57 $66.20 $72.80
Pfizer (NYSE: PFE  ) $17.75 $20.36 $28.60
Merck (NYSE: MRK  ) $36.95 $41.56 $61.60

Source: Capital IQ, a division of Standard & Poor's.

As you can see, Abbott isn't down very far from its 52-week high. But if you bought closer to the peak, now's the time to think back to why you bought it in the first place. If your reasons still hold true, you shouldn't sell just because you have a small loss.

Potential sell signs
First up, we'll get a rough idea of Abbott's valuation. I'm comparing its recent P/E ratio of 15.6 with where it's been over the past five years. 

Source: Capital IQ, a division of Standard & Poor's.

Abbott's P/E is lower than its five-year average, a possible indication that the stock is undervalued. A low P/E isn't always a good sign, since the market may be lowering its valuation of the company because of less attractive growth prospects. But it does indicate that, on a purely historical basis, Abbott Laboratories looks cheap.

Now let's look at the gross-margin trend, which represents the amount of profit a company makes for each $1 in sales, after deducting all costs directly related to that sale. A deteriorating gross margin over time can indicate that competition has forced the company to lower prices, that it can't control costs, or that its whole industry's facing tough times. Here's Abbott's gross margin over the past five years.

Source: Capital IQ, a division of Standard & Poor's.

Abbott is having no trouble maintaining its gross margin, which tends to dictate a company's overall profitability. This is solid news; however, investors need to keep an eye on this metric over the coming quarters. If margins begin to dip, you'll want to know why.

Next, let's explore what other investors think about Abbott. We love the contrarian view here at Fool.com, but we don't mind cheating off our neighbors every once in a while. For this portion of our research, we'll examine two metrics: Motley Fool CAPS ratings and short interest. The former tells us how Fool.com's 170,000-strong community of individual analysts rates the stock, and the latter shows what proportion of investors is betting that the stock will fall. I'm including other peer companies once again for context.

Company

CAPS Rating (out of 5)

Short Interest (% of Float)

Abbott Laboratories 5 0.6%
Johnson & Johnson 5 1.1%
Pfizer 4 0.7%
Merck 4 0.8%

Source: Capital IQ, a division of Standard & Poor's.

The Fool community is rather bullish on Abbott. We typically like to see our stocks rated at four or five stars. Anything below that level is a less-than-bullish indicator. I highly recommend that you visit Abbott's stock-pitch page to see the verbatim reasons behind the ratings.

Here, short interest is at a mere 0.6%. A number like this typically indicates that few large institutional investors are betting against the stock.

Now, let's study Abbott's debt situation, with a little help from the debt-to-equity ratio. This metric tells us how much debt the company's taken on, relative to its overall capital structure.

Source: Capital IQ, a division of Standard & Poor's.

Abbott has been taking on some additional debt over the past five years. With total equity increasing over the same time period, debt-to-equity has consequently remained near its five-year average, as the above chart shows. I consider a debt-to-equity ratio below 50% to be healthy, although the number can vary by industry. Abbott is currently above this level, at 92.8%.

The last metric I like to look at is the current ratio, which lets investors judge a company's short-term liquidity. If Abbott had to convert its current assets to cash in one year, how many times over could it cover its liabilities? As of the last filing, the company has a current ratio of 1.36. Abbott could cover its liabilities, but it's still below a healthy level of 1.5.

Finally, it's highly beneficial to determine whether Abbott belongs in your portfolio -- and to know how many similar businesses already occupy your stable of investments. If you haven't already, be sure to put your tickers into Fool.com's free portfolio tracker, My Watchlist. You can get started right away by adding Abbott Laboratories.

The final recap

Abbott has failed only one of the quick tests that would make it a sell. Does that mean you should hold your shares? Not necessarily. Just keep your eye on these trends over the coming quarters.

Remember to add Abbott Laboratories to My Watchlist to help you keep track of all our coverage of the company on Fool.com.

If you haven't had a chance yet, be sure to read this article detailing how I missed out on more than $100,000 in gains through wrong-headed selling.

True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community.

Jeremy Phillips owns no shares of the companies mentioned. Pfizer is a Motley Fool Inside Value recommendation. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is a Motley Fool Income Investor recommendation. The Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (11)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1342839, ~/Articles/ArticleHandler.aspx, 4/24/2014 2:15:02 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement